658 related items for PubMed ID: 2844399
1. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
Lamberts SW, Uitterlinden P, de Jong FH.
Cancer Res; 1988 Nov 01; 48(21):6063-8. PubMed ID: 2844399
[Abstract] [Full Text] [Related]
2. Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist.
Ward JA, Robinson J, Furr BJ, Shalet SM, Morris ID.
Cancer Res; 1990 Feb 01; 50(3):568-74. PubMed ID: 2137024
[Abstract] [Full Text] [Related]
3. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
Kuber W, Treu T, Kratzik C, Girsch E, Zeillinger R, Spona J.
Wien Klin Wochenschr; 1990 Nov 09; 102(21):640-7. PubMed ID: 2148044
[Abstract] [Full Text] [Related]
4. Inhibition of testosterone production with ketoconazole alone and in combination with a gonadotropin releasing hormone analogue in the rat.
English HF, Santner SJ, Levine HB, Santen RJ.
Cancer Res; 1986 Jan 09; 46(1):38-42. PubMed ID: 3079588
[Abstract] [Full Text] [Related]
5. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
Hjertberg H, Varenhorst E, Svensson M, Kågedal B, Nordenskjöld B.
Acta Oncol; 1988 Jan 09; 27(4):361-4. PubMed ID: 2974290
[Abstract] [Full Text] [Related]
6. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F, Dupont A, Belanger A, Lefebvre FA, Raynaud JP.
J Pharmacol; 1983 Jan 09; 14 Suppl 3():117-35. PubMed ID: 6423907
[Abstract] [Full Text] [Related]
7. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
Schulze H, Senge T.
J Urol; 1990 Oct 09; 144(4):934-41. PubMed ID: 2144596
[Abstract] [Full Text] [Related]
8. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
Lukkarinen O, Kontturi M.
Scand J Urol Nephrol Suppl; 1988 Oct 09; 110():109-12. PubMed ID: 2973121
[Abstract] [Full Text] [Related]
9. Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels.
Gotanda K, Shinbo A, Okada M, Nakano Y, Kobayashi H, Sasaki T, Hagiwara M, Akaza H.
Prostate Cancer Prostatic Dis; 2003 Oct 09; 6(1):66-72. PubMed ID: 12664069
[Abstract] [Full Text] [Related]
10. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
Debruyne FM.
Am J Clin Oncol; 1988 Oct 09; 11 Suppl 1():S33-5. PubMed ID: 2968760
[Abstract] [Full Text] [Related]
11. The different mechanisms for suppression of pituitary and testicular function.
Sandow J, Engelbart K, von Rechenberg W.
Med Biol; 1986 Oct 09; 63(5-6):192-200. PubMed ID: 3010006
[Abstract] [Full Text] [Related]
12. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
Robinson MR, Denis L, Mahler C, Walker K, Stitch R, Lunglmayr G.
Eur J Surg Oncol; 1985 Jun 09; 11(2):159-65. PubMed ID: 3159598
[Abstract] [Full Text] [Related]
13. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
Usami M, Kotake T, Matsuda M, Okajima E, Osafune M, Sonoda T.
Hinyokika Kiyo; 1987 Jan 09; 33(1):141-50. PubMed ID: 2953179
[Abstract] [Full Text] [Related]
14. Pharmacological studies on androgen suppression in therapy of prostate carcinoma.
Sandow J, von Rechenberg W, Engelbart K.
Am J Clin Oncol; 1988 Jan 09; 11 Suppl 1():S6-10. PubMed ID: 3291602
[Abstract] [Full Text] [Related]
15. Long term therapy with a depot LHRH analogue (Zoladex) in patients with advanced prostatic cancer.
Denis L, Keuppens F, Mahler C, Debruyne FM, Weil EH, Lunglmayr G, Newling D, Robinson MR, Richards B, Smith PH.
Prog Clin Biol Res; 1987 Jan 09; 243A():221-7. PubMed ID: 2958852
[No Abstract] [Full Text] [Related]
16. Comparison of the actions of RU 38486 and megestrol acetate in the model of a transplantable adrenocorticotropin- and prolactin-secreting rat pituitary tumor.
Lamberts SW, Uitterlinden P, Bons EG, Verleun T.
Cancer Res; 1985 Mar 09; 45(3):1015-9. PubMed ID: 2982481
[Abstract] [Full Text] [Related]
17. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
Oka H, Negoro H, Sugino Y, Iwamura H, Moroi S, Kawakita M.
Hinyokika Kiyo; 2003 Sep 09; 49(9):521-5. PubMed ID: 14598689
[Abstract] [Full Text] [Related]
18. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
Ahmed SR, Grant J, Shalet SM, Howell A, Chowdhury SD, Weatherson T, Blacklock NJ.
Br Med J (Clin Res Ed); 1985 Jan 19; 290(6463):185-7. PubMed ID: 3155636
[Abstract] [Full Text] [Related]
19. Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors.
Bakker GH, Setyono-Han B, Henkelman MS, de Jong FH, Lamberts SW, van der Schoot P, Klijn JG.
Cancer Treat Rep; 1987 Nov 19; 71(11):1021-7. PubMed ID: 3119199
[Abstract] [Full Text] [Related]
20. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study.
Di Silverio F, Serio M, D'Eramo G, Sciarra F.
Eur Urol; 1990 Nov 19; 18 Suppl 3():54-61. PubMed ID: 2151278
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
